[00043] 425 g of the extractum spissum was diluted with 12 L of 60% ethanol to obtain a raw extract. The raw extract was added to a container containing macroporous resin SP70 (Mitsubishi), which was pre-treated by 10% ethanol. The contents (including the resins and the diluted extract) in the container were stirred and then allowed to stand overnight. The contents were poured into a column. The elution rate of the column was controlled at 1.5- to 2-fold to the volume of the column per hour. The fraction firstly eluted was non-absorbed sample. The column was then eluted through a gradient way by the solvents of 80% ethanol and ethanol:ethyl acetate (1:1), respectively. The volume of each solvent was 4-fold to the volume of the column. The fraction eluted by ethanol:ethyl acetate (1:1) and enriched in dLGG was collected, and was concentrated and dried to obtain 45.82 g of dried product (Cr-E03) with a yield of 10.78%.

Example 2: Component Analysis of the *Crassocephalum crepidioides* Extract

[00044] Conditions for HPLC

Column: Symmetry Shield C18, 15 μm, 4.6 x 150 mm

Temperature: ambient

Elution: H_2O/CH_3CN gradient

Detection: UV 210 nm

Time (min)	Mobile phase (%)	
	H_2O	CH_3CN
0	35	65
10	3.5	96.5
20	3	97
22	0	100
27	0	100
28	35	65
35	35	65

[00045] The spectrum of the *Crassocephalum crepidioides* extract (Cr-E03) is shown in Figure 1. After comparison of Cr-E03 with standards and LCMS-APCI(+), it was confirmed that Peak (5) was dLGG ($[M^+H]^+$: 613, 595 and 335), and that Peak (6) was phytol (M.W. = 296.5).

Example 3: Effects of *Crassocephalum crepidioides* Extract in the Inhibition of the Growth

What is claimed is:

1. A process for preparing an extract of *Crassocephalum crepidioides* comprising the steps of:

(a) contacting *Crassocephalum crepidioides* plant with 70% ethanol to obtain a suspension;

(b) separating the suspension into a solid portion and a liquid portion, and then collecting the liquid portion to obtain a crude extract;

(c) diluting the crude extract to a 60% ethanol extract;

(d) mixing the 60% ethanol extract with macroporous styrene-divinyl benzene resins;

(e) pouring the 60% ethanol extract and macroporous styrene-divinyl benzene resin mixture into a column;

(f) washing the column with ethanol at a volume of about 2- to 10-fold to the volume of the column;

(g) eluting the column with a solvent of ethanol:ethyl acetate (1:1) or ethyl acetate and collecting the eluted fractions at different time intervals; and

(h) analyzing each eluted fraction and determining which one is enriched in 1,2-di-O-α-linolenoyl-3-O-β-galactopyranosyl-sn-glycerol (dLGG) and contains phytol as the *Crassocephalum crepidioides* extract.

2. The process according to claim 1, wherein the *Crassocephalum crepidioides* plant is the whole plant.

3. The process according to claim 1, wherein the *Crassocephalum crepidioides* plant is selected from seeds, flowers, leaves, or any combination thereof.

4. The process according to any one of claims 1 to 3, wherein the *Crassocephalum crepidioides* plant is dried and powdered.

5. The process according to claim 4, wherein the *Crassocephalum crepidioides* plant is a dried plant and the ratio of the weight of the dried plant to the volume of the 70% ethanol solvent in step (a) ranges from 1:1 to 1:50.

6. The process according to claim 5, wherein the ratio of the weight of the dried plant to the volume of the 70% ethanol solvent in step (a) is about 1:10.

7. The process according to any one of the preceding claims, wherein the macroporous styrene-divinyl benzene resin is selected from Sepabeads SP70 and Sepabeads SP710.

8. The process according to claim 7, wherein the macroporous styrene-divinyl benzene resin is Sepabeads SP70.

9. The process according to claim 1, wherein the solvent used in step (g) is ethanol:ethyl acetate (1:1), and wherein the volume ratio of ethanol to ethyl acetate is about 1:1.

10. A *Crassocephalum crepidioides* extract obtainable from the process according to claim 1.

11. The *Crassocephalum crepidioides* extract according claim 10, which has 7 main peaks at the retention times of 12.59 min, 12.893 min, 13.828 min, 14.158 min, 14.922 min, 15.455 min, and 16.478 min, respectively, when determined by HPLC at the following conditions:

Column: Symmetry Shield C18, 15 μm, 4.6 x 150 mm

Temperature: ambient

Elution: H_2O/CH_3CN gradient

Detection: UV 210 nm

Time (min)	Mobile phase (%)	
	H_2O	CH_3CN
0	35	65
10	3.5	96.5
20	3	97
22	0	100
27	0	100
28	35	65
35	35	65

12. A pharmaceutical composition comprising a therapeutically effective amount of the *Crassocephalum crepidioides* extract according to claim 10 and a pharmaceutically acceptable carrier.

13. A pharmaceutical combination comprising a therapeutically effective amount of the *Crassocephalum crepidioides* extract according to claim 10 and a chemotherapeutic agent.

14. The pharmaceutical combination according to claim 13, wherein the chemotherapeutic

agent is selected from a antimetabolite, an alkylating agent, an anthracycline, an antibiotic, an antimitotic agent, and a proteasome inhibitor.

15. The pharmaceutical combination according to claim 13, wherein the chemotherapeutic agent is 5-fluorouracil (5-FU) or epirubicin.

16. Use of the *Crassocephalum crepidioides* extract according to claim 10 the pharmaceutical composition according to claim 12, or the pharmaceutical combination according to claim 13 in the manufacture of a medicament for treating or preventing cancer in a subject in need.

17. Use of the *Crassocephalum crepidioides* extract according to claim 10 or the pharmaceutical composition according to claim 12 in the manufacture of a medicament for treating or preventing cancer in a subject in need in combination with a chemotherapeutic agent.

18. The use according to claim 17, wherein the chemotherapeutic agent is selected from an antimetabolite, an alkylating agent, an anthracycline, an antibiotic, an antimitotic agent, and a proteasome inhibitor.

19. The use according to claim 17, wherein the chemotherapeutic agent is 5-fluorouracil (5-FU) or epirubicin.

20. The *Crassocephalum crepidioides* extract according to claim 10 or the pharmaceutical combination according to any one of claims 12 to 15 for use in treating or preventing cancer.

21. The *Crassocephalum crepidioides* extract according to claim 10 or 11 or the pharmaceutical composition according to claim 12, or the pharmaceutical combination according to claim 13 for use in treating or preventing cancer in combination with a chemotherapeutic agent.

22. The *Crassocephalum crepidioides* extract or the pharmaceutical composition for use according to claim 21, wherein the chemotherapeutic agent is selected from an antimetabolite, an alkylating agent, an anthracycline, an antibiotic, an antimitotic agent, and a proteasome inhibitor.

23. The *Crassocephalum crepidioides* extract or the pharmaceutical composition for use according to claim 21, wherein the chemotherapeutic agent is 5-fluorouracil (5-FU) or epirubicin.